In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.

• Keywords
• COVID-19, Cardiovascular complications, Diabetes, Intensive Care Unit,
• MeSH
• Antihypertensive Agents therapeutic use   MeSH
• Betacoronavirus pathogenicity   MeSH
• Biomarkers blood   MeSH
• COVID-19 MeSH
• Diabetes Mellitus blood   diagnosis   drug therapy   mortality   MeSH
• Dyslipidemias drug therapy   mortality   MeSH
• Risk Assessment MeSH
• Hypertension drug therapy   mortality   MeSH
• Hypoglycemic Agents adverse effects   therapeutic use   MeSH
• Host-Pathogen Interactions MeSH
• Intensive Care Units * MeSH
• Coronavirus Infections diagnosis   mortality   therapy   virology   MeSH
• Blood Glucose drug effects   metabolism   MeSH
• Humans MeSH
• Pandemics MeSH
• Risk Factors MeSH
• SARS-CoV-2 MeSH
• Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use   MeSH
• Pneumonia, Viral diagnosis   mortality   therapy   virology   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Names of Substances
• Antihypertensive Agents MeSH
• Biomarkers MeSH
• Hypoglycemic Agents MeSH
• Blood Glucose MeSH
• Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH